High-risk

49 drugs in development·30 companies·2 clinical trials

Drug Pipeline by Phase

Approved(13)

Drug	Company
abiraterone	Mersana Therapeutics, Inc. (MRSN)
abiraterone	Aptinyx Inc. (APTX)
abiraterone	DR REDDYS LABORATORIES LTD (RDY)
abiraterone	Mylan II B.V. (MYL)
cervicalstim	Orthofix Medical Inc. Common Stock (DE) (OFIX)
danyelza	Y-mAbs Therapeutics, Inc. (YMAB)
enzalutamide	Aptinyx Inc. (APTX)
enzalutamide	X4 Pharmaceuticals, Inc (XFOR)
nadofaragene firadenovec	CG Oncology, Inc. (CGON)
Unituxin	UNITED THERAPEUTICS Corp (UTHR)
vascepa	AMARIN CORP PLCUK (AMRN)
vascepa	AMARIN CORP PLCUK (AMRN)
vonjo	CTI BIOPHARMA CORP (CTIC)

Phase 3(8)

Drug	Company
AR-320	Aridis Pharmaceuticals, Inc. (ARDS)
AXAL (axalimogene filolisbac / ADXS-HPV)	Ayala Pharmaceuticals, Inc. (ADXS)
axicabtagene ciloleucel	GILEAD SCIENCES, INC. (GILD)
CAN-2409	Candel Therapeutics, Inc. (CADL)
cretostimogene	CG Oncology, Inc. (CGON)
cretostimogene grenadenorepvec	CG Oncology, Inc. (CGON)
eb613	Entera Bio Ltd. (ENTX)
Etoposide	PTC THERAPEUTICS, INC. (PTCT)

Phase 2(23)

Drug	Company
4D-125 IVT Injection	Replimune Group, Inc. (REPL)
Cytoxan	Filana Therapeutics Inc. (FLNA)
Cytoxan	ENANTA PHARMACEUTICALS INC (ENTA)
Cytoxan	Merus N.V. (MRUS)
Cytoxan	PTC THERAPEUTICS, INC. (PTCT)
DANYELZA	PTC THERAPEUTICS, INC. (PTCT)
DANYELZA	Filana Therapeutics Inc. (FLNA)
DANYELZA	Merus N.V. (MRUS)
DANYELZA	ENANTA PHARMACEUTICALS INC (ENTA)
dare-hpv	Dare Bioscience, Inc. (DARE)
detalimogene	ENGENE HOLDINGS INC. (ENGN)
ETBX-071	ImmunityBio, Inc. (IBRX)
Ifosfamide	ENANTA PHARMACEUTICALS INC (ENTA)
Ifosfamide	Filana Therapeutics Inc. (FLNA)
M-CENK	ImmunityBio, Inc. (IBRX)
Sargramostim	Merus N.V. (MRUS)
Sargramostim	ENANTA PHARMACEUTICALS INC (ENTA)
Sargramostim	Filana Therapeutics Inc. (FLNA)
Temozolomide	Filana Therapeutics Inc. (FLNA)
Topotecan	Filana Therapeutics Inc. (FLNA)
Topotecan	ENANTA PHARMACEUTICALS INC (ENTA)
Topotecan	PTC THERAPEUTICS, INC. (PTCT)
VTP-200	Barinthus Biotherapeutics plc. (BRNS)

Phase 1(5)

Drug	Company
ACLX-002	Arcellx, Inc. (ACLX)
DVX201 (Unmodified Natural Killer Cells)	Coeptis Therapeutics Holdings Inc. (COEP)
gtb-3650	GT Biopharma, Inc. (GTBP)
inb-100	IN8BIO, INC. (INAB)
sgr-2921	Schrodinger, Inc. (SDGR)

BioSniper tracks 49 drugs in development for High-risk across 30 companies.

There are 2 clinical trials targeting High-risk tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.